Last reviewed · How we verify

Low Dose Acetazolamide — Competitive Intelligence Brief

Low Dose Acetazolamide (Low Dose Acetazolamide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Carbonic anhydrase inhibitor. Area: Ophthalmology; Pulmonology.

marketed Carbonic anhydrase inhibitor Carbonic anhydrase II Ophthalmology; Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Low Dose Acetazolamide (Low Dose Acetazolamide) — University of Utah. Acetazolamide inhibits carbonic anhydrase to reduce bicarbonate reabsorption in the kidney, promoting diuresis and alkalinizing urine while lowering intraocular pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Low Dose Acetazolamide TARGET Low Dose Acetazolamide University of Utah marketed Carbonic anhydrase inhibitor Carbonic anhydrase II
Azopt BRINZOLAMIDE Novartis marketed Carbonic Anhydrase Inhibitor [EPC] carbonic anhydrase II 1998-01-01
ACETAZOLAMIDE oral capsule ACETAZOLAMIDE oral capsule University of Zurich marketed Carbonic anhydrase inhibitor Carbonic anhydrase II
Latanoprost, Dorzolamide Latanoprost, Dorzolamide Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia marketed Prostaglandin analog + Carbonic anhydrase inhibitor combination Prostaglandin F receptor (FP receptor) and Carbonic anhydrase II
Simbrinza 0.2%-1% Ophthalmic Suspension Simbrinza 0.2%-1% Ophthalmic Suspension Prairie Eye Center marketed Fixed-dose combination of carbonic anhydrase inhibitor and alpha-2 adrenergic agonist Carbonic anhydrase II; alpha-2 adrenergic receptor
timolol maleate and dorzolamide hydrochloride timolol maleate and dorzolamide hydrochloride University of Florida marketed Beta-adrenergic antagonist and carbonic anhydrase inhibitor combination Beta-2 adrenergic receptor (timolol); carbonic anhydrase II (dorzolamide)
tafluprost and dorzolamide/timolol tafluprost and dorzolamide/timolol Aristotle University Of Thessaloniki marketed Prostaglandin analogue / carbonic anhydrase inhibitor / beta-blocker combination Prostaglandin F receptor (FP receptor), carbonic anhydrase II, beta-1 and beta-2 adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Carbonic anhydrase inhibitor class)

  1. Bausch & Lomb Incorporated · 2 drugs in this class
  2. Actavis Inc. · 2 drugs in this class
  3. Beijing Tiantan Hospital · 1 drug in this class
  4. Merck Sharp & Dohme LLC · 1 drug in this class
  5. National University Hospital, Singapore · 1 drug in this class
  6. Padagis LLC · 1 drug in this class
  7. Rabin Medical Center · 1 drug in this class
  8. Shahid Beheshti University of Medical Sciences · 1 drug in this class
  9. Sun Pharmaceutical Industries Limited · 1 drug in this class
  10. University Health Network, Toronto · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Low Dose Acetazolamide — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-acetazolamide. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: